Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Metabolism And Disposition

• Publication date

  2011-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.110.035899PMID 21245287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population

  2010cited by this paper
• Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement

  2009cited by this paper
• Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population

  2009cited by this paper
• Identification of New CYP2C19 Variants Exhibiting Decreased Enzyme Activity in the Metabolism of S-Mephenytoin and Omeprazole

  2009cited by this paper
• Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

  2009cited by this paper
• Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism

  2008cited by this paper
• CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population

  2007cited by this paper
• Comparisons of CYP2C19 Genetic Polymorphisms Between Korean and Vietnamese Populations

  2007cited by this paper
• Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

  2006cited by this paper
• Effect of Quercetin on the Pharmacokinetics of Rosiglitazone, a CYP2C8 Substrate, in Healthy Subjects

  2005cited by this paper
• Genetic Polymorphism of CYP2C9 in a Vietnamese Kinh Population

  2005cited by this paper
• Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity

  2005cited by this paper
• FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION

  2005cited by this paper
• Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance

  2005cited by this paper
• Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects

  2004cited by this paper
• Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone

  2004cited by this paper
• Genetic polymorphisms of CYP2C8 in Japanese population.

  2003cited by this paper
• Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.

  2003cited by this paper
• Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.

  2003cited by this paper
• 5,6-Epoxyeicosatrienoic Acid Mediates the Enhanced Renal Vasodilation to Arachidonic Acid in the SHR

  2003cited by this paper
• CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

  2002cited by this paper
• Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift.

  2002cited by this paper
• P-450 metabolites of arachidonic acid in the control of cardiovascular function.

  2002cited by this paper
• Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

  2001cited by this paper
• Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid.

  2001cited by this paper
• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

  2001influential reference
• Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.

  2000cited by this paper
• Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs

  1999cited by this paper
• Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

  1997cited by this paper

• Evaluation of the Effectiveness and Safety of Lorlatinib in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non-Small Cell Lung Cancer

  2025cites this paper
• Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions.

  2024cites this paper
• The Role of CYP3A4 and CYP2C8 Polymorphism on Amiodarone Responses: Review Article

  2023cites this paper
• Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

  2023cites this paper
• Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells

  2021cites this paper
• Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells

  2021cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020influential citation
• Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

  2019cites this paper
• Although ABCC 8 1369 Ala and KCNJ 11 23 K variants

  2018cites this paper
• Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals

  2017cites this paper
• Pharmacogenomics of Type 2 Diabetes Mellitus

  2017cites this paper
• Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human.

  2017cites this paper
• Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs

  2016cites this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016cites this paper
• Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?

  2015cites this paper
• Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries

  2015cites this paper
• Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations

  2015cites this paper
• Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus

  2015cites this paper
• Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.

  2015cites this paper
• Pharmacogenomics of Oral Antidiabetic Drugs

  2014cites this paper
• Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations

  2014cites this paper
• Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans.

  2014cites this paper
• Cytochrome P450 2C8 and drug metabolism.

  2013cites this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cites this paper
• The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs

  2013cites this paper
• CYP2C8 Polymorphism Frequencies Among Han, Uighur, Hui, and Mongolian Chinese Populations

  2013cites this paper
• Pharmacogenetics of Oral Antidiabetic Drugs

  2013cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper